The development momentum of biotechnology in China is like a rainbow

With the rapid development of science and technology, the market for bioengineering and new drugs is extremely active. Especially in the past few years, when China has gradually integrated with the world pharmaceutical market, the biomedical industry has risen rapidly. Under the speculation of the stock market, the manufacturing industry, which is dominated by chemical drugs, is rapidly approaching the products of bioengineering technology. Today, with the slow development of chemical innovative drugs, the globalization of bioengineered drugs has become increasingly prominent, and has attracted more attention.
Genetic products are springing up
Biotechnology drugs refer to protein, antibody or nucleic acid drugs developed by using DNA recombination technology or monoclonal antibody technology, or other new biological technologies. They are the most active, fastest growing and most fruitful fields in modern science. These drugs have been widely used to treat many difficult diseases, and the market for biotechnology drugs has also developed rapidly like mushrooms.     
The research achievements of recombinant protein and peptide drugs, recombinant DNA drugs, molecular cloning, gene recombination technology, and microecological agents have gradually entered into commercialization. Among them, there are many recombinant protein and peptide drugs that have been developed and marketed, mainly including cytokines: interleukin, interferon, tumor necrosis factor, epidermal growth factor; Recombinant thrombolytic drugs: recombinant streptokinase, recombinant staphylokinase, humanized monoclonal antibody preparation; As well as recombinant vaccines and antiviral drugs. The recombinant DNA drugs in the research and development stage include oligonucleotide drugs, antisense nucleosides, gene drugs and cell therapy preparation vaccines. By the beginning of 2004, there were more than 2200 kinds of biotech drugs under development in the world, and the United States had approved more than 170 kinds of biotech drugs. These new products are causing changes in the market.   
According to the report of the DCAT meeting held by IMS Health in New York in March 2004, in recent years, the global sales of biopharmaceuticals have grown at an average annual rate of 30%. In 2003, the global biopharmaceutical market value reached 37 billion dollars. Among the "blockbuster" drugs, the proportion of biotech drugs will be increasing, and the biotech products in the clinical research stage account for 1/4 of all drugs developed, It has become a growth point driving the profits of the global pharmaceutical market.

Rapid growth of biological industry
Biotechnology drugs are the key project of China's development. Since the 1980s, great progress has been made, and they have gradually developed from biological products, biochemical drugs, and microbial drugs to bioengineering drugs. Through continuous efforts, many biopharmaceutical enterprises and scientific research institutes have made full use of this most efficient lead compound on the basis of natural biochemical drugs, and have made certain achievements. Its representative product recombinant human interferon α 1b The success of research and development marks the substantial progress of DNA recombination technology. With the joint cooperation between biotechnology and pharmaceutical industry, as well as the continuous integration of multiple resources. At present, there are more than 200 biopharmaceutical enterprises in China, and about 1/3 of them have genetic engineering drug product projects.        
China's gene technology research and development started late. The bioengineering pharmaceutical industry is an emerging industry, which has a big gap with developed countries, mainly in small scale, few varieties, and insufficient innovation ability. This is an indisputable fact. However, the research and development of products has taken a short path, which is characterized by a fast start. To be exact, since 1989, the first bioengineered drug in China β－ Since the introduction of interferon, 21 kinds of genetic engineering drugs, including recombinant human interferon, erythropoietin, interleukin-2, human growth factor, staphylokinase, recombinant modified human tumor necrosis factor, nerve growth factor and human insulin, have been put on the market in China by 2003, of which nearly 1/3 are national innovative drugs. There are also more than 10 varieties in clinical research. Although many projects are still in the research stage, the rapid development of bioengineering technology has become a bright spot in the pharmaceutical market and will certainly become the fastest growing part of the pharmaceutical industry.

　　

Power comes from the market
In recent years, with the impact of ecological environment, increasing life pressure and the growth of age, the prevalence of malignant tumors has gradually increased. The spread of immunodeficiency virus, hepatitis B and hepatitis C virus diseases has jointly promoted the market of gene technology drugs, and has shown a rapid development.          
However, on the other hand, the development of China's biopharmaceutical industry was not smooth. After the rapid growth stage in the middle and late 1990s, the biopharmaceutical industry also experienced a period of low tide in the ebb and flow of the world spring tide and the low-key operation of the domestic stock market. In 2002, the listed companies mainly engaged in biopharmaceutical business also showed poor performance and slow development due to leading product factors.           
The development of the market also has its special track, which is not transferred by people's will. Due to the sudden impact of SARS virus, biological drugs such as interferon and thymosin have become the best prescription for controlling SARS, which has also made the biopharmaceutical sector widely concerned again, promoting the development of the biopharmaceutical market and the successful listing of small and medium-sized high-tech enterprises such as Beijing Shuanglu Pharmaceutical. Looking forward to the future, the biomedical industry will take this opportunity to drive the breakthrough of technical barriers with the development of new products and open up new biomedical markets, which will enable China's bioengineering and pharmaceutical industries to join hands on a higher development platform.           
In recent years, China's pharmaceutical industry has shown a sustained and rapid growth trend. In 2003, the sales revenue of the national pharmaceutical industry reached 296.2 billion yuan, an increase of 19% over the previous year, and the profit was 27.4 billion yuan, an increase of 25.8% over the previous year. Pharmaceutical restructuring and M&A are in full swing: the eight most active pharmaceutical systems in the capital field, namely Huayuan, Fosun, Taiji, Madame, Dongsheng, Yuanda, Huali and China Resources, have emerged. The "Medicine Valley" craze has attracted huge investment: at present, there are more than 100 pharmaceutical industrial parks of all kinds in China, and more than 50 biological pharmaceutical parks have been approved by relevant national departments or local governments.           
From the perspective of bioengineering and pharmaceutical industry in Beijing, the current output value in 2003 has reached 15 billion yuan, with the total profit accounting for 14.57%. From the structural analysis, the proportion of chemical pharmacy, bioengineering and natural drugs is 50:17:33, and the total output value of bioengineering pharmaceutical industry is 1.67 billion yuan. In the next step, the government will encourage the focus on the industrial research of biological information technology, biochip technology, gene therapy technology, cell therapy technology, etc., and encourage the development of biological diagnostic chips, cell immunotherapy drugs, monoclonal antibody diagnostic reagents, genetic engineering drugs, vaccines and other products.          
Reviewing the development of biotechnology drugs, after more than 30 years of wandering, it has begun to take shape. In the drug market, biotechnology drugs have become an important category of drugs, which are mainly used for the treatment of cancer, human immunodeficiency virus diseases, cardiovascular diseases, diabetes, anemia, autoimmune diseases, gene defects and many genetic diseases. The development of biotechnology is changing with each passing day, thus promoting the research process of gene recombinant DNA technology, molecular cloning technology, and cell fusion technology.           
Facing the situation of economic globalization, the bio genetic engineering industry has a good opportunity for development at any time. In the process of bio genetic engineering research, enlarged production and market development, China has a big gap with developed countries in terms of management system, capital, technology and talents. At the same time, it is also very weak in patent protection and patent research, which is known as the fatal "soft rib". Only by accelerating the adjustment of the industrial structure, improving the quality and efficiency, rationally allocating limited resources, and thus forming a scientific and reasonable R&D and production pattern, can the development of the new biological industry be beneficial.